My Life on this planet.

This is an older text (from around 2013-2014) that I didn't publish earlier, among other reasons because my internet was down and afterwards the moment was gone, hence some links to older articles. But now it seems to be another moment to publish the updated article as part of my miniseries about the pharmaceutical sector to show it is much more than "only for the money" although I acknowledge there are excesses. As a reminder:  - The first article was about the obligations pharmaceutical companies have to continue to monitor the safety of their products after commercialisation and if needed companies must update the product information, a cost for the companies.  - The second article described how the product information of codeine-containing products had major updates long after it was first used because new data became available as a result of its use in clinical practice and because it can interfere with  new drugs.  -  This third article describes the process from